碘帕醇(Iopamidol) - 在研适应症：造影剂_专利_临床

概要

基本信息

药物类型

造影剂、小分子化药

别名

Iopamidol (JP17/USP)、SHL429、SQ-13396

+ [14]

靶点-

作用方式

增强剂

作用机制

射线照相增强剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Bayer Yakuhin Ltd.Bracco Diagnostics, Inc.Central Medical Service Co. Ltd.

非在研机构-

权益机构

海南普利制药股份有限公司

最高研发阶段批准上市

首次获批日期

日本 (1985-11-05),

造影剂

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C17H22I3N3O8

InChIKeyXQZXYNRDCRIARQ-LURJTMIESA-N

CAS号60166-93-0

关联

37

项与碘帕醇相关的临床试验

NCT06411795

/ Recruiting临床2期IIT

Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy: A Prospective, Randomized, Non-Inferiority Trial

This phase II trial compares the effect of rectus sheath block with liposomal bupivacaine to thoracic epidural analgesia (TEA) on pain control in patients following surgical removal of all or part of the pancreas and duodenectomy (pancreatoduodenectomy). Administering long acting local anesthetics, such as liposomal bupivacaine, in between the muscle layers of the abdomen (rectus sheath block) may help with pain relief during and after surgery. TEA uses a needle to insert a flexible plastic catheter into the thoracic spine to administer anesthetic and pain medication, such as bupivacaine and hydromorphone, to treat pain in the thoracic and upper abdominal areas during and after surgery. Epidurals have been successfully used to treat pain after surgery, however, it does have a risk of low blood pressure which may limit the use in the thoracic approach. Rectus sheath blocks with liposomal bupivacaine may be as effective as TEA in reducing pain in patients following a pancreatoduodenectomy.

开始日期2023-11-10

申办/合作机构

University of Minnesota Masonic Cancer Center

[+1]

NCT05489055

/ RecruitingN/A

Department of Radiology

Extrinsic prewarming of iodinated CT contrast media (CM) to body temperature reduces viscosity and injection pressures. However, guideline recommendations on the necessity to prewarm iodinated CM are conflicting. And studies examining the effect of extrinsic warming CM for coronary CTA(CCTA) on clinical adverse events and image quality are lack.
Enrolled patients of chest pain or coronary artery disease screening were eligible for this a double-blinded, randomized noninferiority trial, and equally allocated into two group randomly: BBT-CM (basic body temperature) group received 37°C CM; RT-CM (room temperature) group received
23°C CM. A state-of-the-art individualized CM (iopamidol at 370 mg I/mL) injection protocol was used, based on body weight.

开始日期2022-02-01

申办/合作机构

重庆市急救医疗中心（重庆市第四人民医院、重庆市急救医学研究所）

NCT05031520

/ TerminatedN/AIIT

A Single Center Study of Perivascular Coronary Inflammation in Patients With Myocardial Ischemia or Infarction With Non-Obstructive Coronary Arteries

Among patients with ischemic heart disease who are referred for coronary angiography, a substantial proportion have non-obstructive coronary artery disease (CAD). Myocardial infarction (MI) with non-obstructive coronary artery disease (MINOCA) accounts for 5-20% of patients with MI and preferentially affects women. MINOCA pathogenesis is varied and may include atherosclerotic plaque rupture, plaque erosion with thrombosis, vasospasm, embolization, dissection or a combination of mechanisms. Other patients may have clinically unrecognized myocarditis, or takotsubo syndrome masquerading as MI. Among patients referred for coronary angiography for the evaluation of stable ischemic heart disease, non-obstructive CAD is present in up to
30% of men and
60% of women. Stable ischemia with non-obstructive coronary arteries (INOCA) may be due to coronary microvascular dysfunction in up to 40% of these patients. Our understanding of mechanisms of MINOCA and INOCA remain incomplete. Coronary inflammation has been hypothesized as a potential mechanism contributing to coronary spasm in MINOCA and microvascular disease in INOCA.

开始日期2021-07-12

申办/合作机构

NYU Langone Health

100 项与碘帕醇相关的临床结果

登录后查看更多信息

100 项与碘帕醇相关的转化医学

登录后查看更多信息

100 项与碘帕醇相关的专利（医药）

登录后查看更多信息

1,860

项与碘帕醇相关的文献（医药）

2026-07-01·Small science

Na/Cu‐Doping Engineering of Carbon Nitride for High‐Performance Visible‐Light Degradation of Iopamidol

Article

作者: Reis, Nuno M. ; Ashu Abey, Samuel ; Fernandes, Carl ; Emanuelsson, Emma ; Expósito, Antonio J.

Visible‐light‐driven photocatalytic generation of hydroxyl radicals provides a sustainable pathway for the photodegradation of emerging contaminants. Particularly, carbon nitride (g‐C 3 N 4 ) is a promising photocatalyst for the removal of emerging contaminants; however, it suffers from a limited surface area and a bandgap that restricts its visible‐light photocatalytic efficiency. To overcome these limitations, this study presents a novel copper–sodium codoped graphitic carbon nitride (NaCu‐g‐C 3 N 4 ) photocatalyst with enhanced visible‐light photocatalytic activity tested for the degradation of Iopamidol, a persistent and toxic pollutant resistant to conventional wastewater treatment plants. The codoping of Na and Cu was strategically employed to reduce the bandgap energy, enhance visible‐light absorption, and increase the surface area, thereby improving the photocatalytic activity of carbon nitride. When combined with the oxidizing agent H 2 O 2 , the system accelerated the formation of oxidizing radicals. The synergy of NaCu‐g‐C 3 N 4 and H 2 O 2 yielded 82.3% degradation of Iopamidol within 120 min under visible light at pH 3, marking the highest and first successful reported visible‐light‐driven degradation of Iopamidol. These findings highlight the potential of NaCu‐g‐C 3 N 4 as a cost‐effective semiconductor photocatalyst for the efficient and sustainable removal of persistent pollutants.

2026-06-30·FASEB JOURNAL

Salvianolic Acid B Protects Against Contrast‐Induced Acute Kidney Injury by Attenuating Ferroptosis via the SIRT1 /Nrf2 Pathway

Article

作者: Yuan, Hongtao ; Xie, Shuangshuang ; Zhang, Yutong ; Yuan, Yinuo ; Zhang, Chen ; Qin, Jiaming ; Shi, Xiang ; Chen, Lihua ; Wang, Yiran ; Wang, Yue ; Zhu, Jinxia ; Shen, Wen

ABSTRACT:

Contrast‐induced acute kidney injury (CI‐AKI) poses a significant clinical challenge and contributes to a considerable healthcare burden. Ferroptosis has been increasingly recognized as an important mechanism of renal tubular epithelial cell injury in CI‐AKI. Salvianolic acid B (SalB), a natural compound with anti‐inflammatory and antioxidant properties, has shown protective effects in various kidney diseases. However, its role in CI‐AKI‐associated ferroptosis has not been fully clarified. In this study, we established a rat model of CI‐AKI by subcutaneous injection of carbon tetrachloride for 6 weeks followed by iopamidol administration, and an in vitro model using iopamidol‐treated HK‐2 cells. Effects of tubular injury and ferroptosis were examined both in vivo and in vitro. Cycloheximide chase assay, cellular thermal shift assay, and molecular docking were used to assess the binding capacity of SalB to SIRT1. Our results showed that SalB significantly alleviated renal injury, reduced iron accumulation, oxidative stress levels, and lipid peroxidation, upregulated the expression of SLC7A11 and GPX4, and downregulated ACSL4 expression in both iopamidol‐treated rat kidneys and HK‐2 cells. Mechanistically, SalB targeted and bound to SIRT1, enhancing its stability, thereby promoting Nrf2 upregulation and nuclear translocation, which in turn enhanced the expression of SLC7A11 and GPX4 and attenuated ferroptosis. Silencing either SIRT1 or Nrf2 in HK‐2 cells partially abrogated the protective effect of SalB. Collectively, our results support SalB as a viable treatment strategy for CI‐AKI.

2026-06-22·Chemical & biomedical imaging

Peptide-Based pH-Responsive MRI-CEST Agents: In Vivo Comparison between a Selected Pentapeptide and the Established Iopamidol Reference in Tumor pH Mapping Ability

Article

作者: Aime, Silvio ; Carella, Antonella ; Salvatore, Marco ; Gammaraccio, Francesco ; Gallo, Enrico ; Accardo, Antonella ; Longo, Dario Livio

Magnetic resonance imaging based on chemical exchange saturation transfer (MRI-CEST) has emerged as a powerful imaging technique for mapping physiological parameters, such as tissue pH, with high spatial resolution. This study explores the pH-responsive performance of a novel peptide-based CEST agent, selected among several candidates, when compared with the established contrast agent iopamidol. The selected hLys containing pentapeptide showed enhanced sensitivity and biocompatibility while maintaining an excellent CEST response. In vivo MRI studies further assessed its applicability for tumor pH imaging. The results demonstrate that the selected peptide-based agent displays good CEST contrast variations in response to pH changes, highlighting its potential as a pH-responsive CEST agent. The assessed pH values were very similar to those obtained upon the administration of iopamidol, a well-established pH-CEST agent. Notably, this result was obtained by administering a mass dose of contrast agent that is about 8-fold less than that used in the case of iopamidol. These findings pave the way for the development of peptide-derived MRI probes for noninvasive tumor microenvironment assessment.

214

项与碘帕醇相关的新闻（医药）

2026-10-19

·普利制药

韩国客户到访安徽普利，共探BPA硼药国际合作新机遇

韩国客户到访安徽普利，共探BPA硼药国际合作新机遇开放合作·共拓硼药全球市场前言 10月15日，韩国客户一行到访安徽普利药业有限公司，围绕BPA（硼 [10B] 法仑原料药）开展实地考察与商务洽谈。安徽普利李总及相关业务负责人接待来访团队，双方就产品质量标准、供应链保障、国际注册协同、下一代创新硼药管线合作等议题开展深度交流，共商 BNCT 硼药领域国际化合作路径。 PART 01 技术互信：立足国际化质量体系，夯实硼药创新产业根基安徽普利向韩国客户全面介绍企业发展概况，重点阐述公司BNCT 硼药全球化战略布局。除成熟的硼[10B]法仑原料药自主产业化成果（原料纯度≥99.9%、10B丰度≥99%）之外，也向来访客户展示公司完整的BNCT创新药物研发平台。平台突破传统BPA靶点局限，布局代谢靶向小分子、BDC硼偶联药物等多条差异化在研管线，构建起成熟产品+源头创新的完整技术矩阵。作为深耕医药国际化赛道的企业，公司对标全球最高标准搭建完整质量管控体系，持续推进硼药创新成果的海外转化。来访韩国客户介绍其区域市场需求与长期合作构想，双方围绕 BPA 稳定供应、跨国注册支持、创新管线联合开发、可持续战略合作方向充分交换意见，建立技术层面的深度互信。 PART 02 现场验证：国际化cGMP体系实地核验，彰显原料药硬实力韩国客户先后参观公司 QC 实验室与原料药生产现场。在 QC 实验室，客户详细调研 BPA 全流程检测方案与国际化质量控制体系；走进生产车间，实地察看设备运维、工艺管控与现场管理水平。客户对安徽普利接轨欧美的 cGMP 质量管理体系、标准化生产能力给予积极评价。安徽普利坚持以国际化体系为底座，以全球监管标准约束研发、生产全链条，既保障现有原料药稳定出海，也为后续创新硼药的全球产业化落地筑牢生产与质量底座，支撑创新原料药面向全球市场输出。 PART 03 合作展望：深化跨国交流，BPA合作洽谈取得积极进展经过实地走访与多轮技术、商务沟通，韩国客户对安徽普利 BPA 产品品质、持续供货能力表示高度认可，双方就 BPA 业务达成初步合作意向。依托BPA原料药过硬的产品实力与完整的国际注册能力，普利硼药已成功实现海外市场落地。本次跨国交流为 BNCT 硼药进一步拓展东亚市场创造有利条件，是普利硼药全球化布局进程中的重要阶段性进展安徽普利作为普利制药旗下核心原料药生产基地，实现硼 [10B] 法仑原料药自主量产，该产品已向美国FDA提交 DMF文件（DMF号：44131），实现品种国际化。BPA规模化量产，年产能可达500公斤，可稳定供应全球临床、科研及制剂企业，无供货缺口。普利制药始终坚持创新国际化道路，在夯实现有原料药与制剂出海的同时，持续推进PL009、PL012等新一代靶向硼药、BDC硼偶联药物的研发与全球布局，推动中国自主BNCT硼药技术出海，助力国产创新原料药惠及全球肿瘤患者。欢迎垂询，共话国际合作！业务联系：lisubin@hnpoly.com PART 04 关于安徽普利安徽普利药业有限公司，成立于2018年，坐落于安庆国家高新技术产业开发区。是一家活性原料专业供应商，向全球医药、保健和护肤领域提供化学合成、生物合成的高品质特色原料。安徽普利药业拥有强大高效的研发和生产团队、配备现代化生产设施、建立严格地欧美高端原料药cGMP质量体系和高标准EHS体系，为客户提供高品质原料药和中间体的同时，也提供CDMO、工艺技改等。公司目前拥有3个符合欧美中GMP标准的API 生产车间、10条生产线，357台多功能设备。依托强大的研发能力和技术转化能力，已完成造影剂（钆特酸葡胺、钆特醇、钆布醇、碘美普尔、碘普罗胺、碘佛醇、碘帕醇、碘克沙醇等）、合成生物学（司美格鲁肽、依克多因、红景天苷）、抗肿瘤（环磷酰胺）、其他原料药（氢氧化镁、阿普斯特、克立硼罗、伏立康唑、盐酸美金刚）、其他药用辅料（DOTA、SNAC、磺丁基-β-环糊精钠、卡特利多钙、考布曲钙）等系列产品的商业化研发与生产。自成立以来，安徽普利已多次通过中国、美国等国际主流监管机构的官方认证，质量管理体系的稳定性与持续改进能力获得广泛认可。免责及前瞻性声明（Disclaimer & Forward-Looking Statement）本文仅作医药科普与企业信息介绍之用，内容整合公开披露资料及公司研发进展摘要，仅供参考。文中药品、项目相关表述不构成医疗诊疗建议、投资建议，亦不承诺未来相关成果；委托生产、原料药供应等合作安排需完成质量体系搭建与合规注册，最终以监管部门批复为准。本文所载数据、观点均基于文稿发布当日公开信息，公司不承担持续更新义务。文中涉及注册申报、市场规划、业务发展等前瞻性陈述，均依托现有信息及合理假设作出，存在不确定性；受市场环境、行业政策等各类风险因素影响，实际情况或与预判存在较大差异，公司无义务因后续变动修订相关内容，敬请读者充分知悉风险、审慎判断。 -END-

2026-09-07

·米内网

【瞩目】30亿注射剂，南京正大天晴获批

精彩内容日前，南京正大天晴申报的4类仿制药碘佛醇注射液获批生产并视同过评，为公司获批的第4款造影剂。米内网数据显示，近年来中国三大终端六大市场碘佛醇注射液销售额均超过30亿元。碘佛醇注射液为国家医保甲类、国家基药品种，是一款非离子型、双聚体对比剂，适用于成人和儿童心血管系统造影、头部和体部CT增强扫描及静脉排泄性尿路造影等。米内网数据显示，近年来中国三大终端六大市场（统计范围详见本文末）碘佛醇注射液销售额均达30亿元以上，2026年一季度以超11%的增速继续放量，在造影剂（化药）产品排名中稳居榜首。近年来中国三大终端六大市场碘佛醇注射液销售情况（单位：万元）来源：米内网格局数据库碘佛醇注射液已满足国采入围门槛，目前有圣华曦、司太立、重庆药友制药、倍特药业、恒瑞医药、北京北陆药业、南京正大天晴等10家企业过评或视同过评。此前，南京正大天晴已有3款造影剂获批生产并视同过评，分别为碘普罗胺注射液、碘克沙醇注射液及碘帕醇注射液。此外，八氟丙烷脂质微球注射液以新注册分类报产在审，该药在国内暂无首仿获批。今年以来，南京正大天晴有3个品种获批生产并视同过评。其中，苯磺酸美洛加巴林片为国内首仿+首家过评，原研产品2026年一季度在中国三大终端六大市场的销售额增速超过1200%。今年以来南京正大天晴获批上市的仿制药来源：米内网中国申报进度（MED）数据库此外，今年以来，南京正大天晴有8个品种以新注册分类报产获受理。其中，甲苯磺酸尼拉帕利胶囊、雷美替胺片等暂无仿制药获批，注射用甲磺酸萘莫司他、琥珀酰明胶电解质醋酸钠注射液等获批的企业仅有1家。资料来源：米内网数据库、国家药监局官网等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至9月7日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。

上市批准

2026-09-04

·普利制药

压实责任，筑牢防线——安徽普利传达落实企业安全生产主体责任精神

安徽普利药业 STAY COMMITTED TO SAFE DEVELOPMENT 压实责任，筑牢防线有效落实企业安全生产主体责任精神内容简要 8月24日至28日，安徽省应急管理厅与中共安徽省委党校（安徽行政学院）联合举办全国化工企业落实安全生产主体责任视频培训班（安徽省分课堂）。安徽普利厂长李总参加培训，系统学习了安全生产最新政策要求与管理实践。培训归来后，李总第一时间面向企业员工传达会议精神，并对安徽普利安全生产工作作出重要部署。李总结合培训内容，重点传达了四大核心要点。 01 安全管理趋势持续收紧，必须警钟长鸣当前安全生产监管力度持续加大、标准日趋严格，企业必须牢固树立“红线意识”，不能有任何侥幸心理和松懈思想。安全是企业发展的生命线，必须摆在压倒性位置常抓不懈。 02 聚焦关键环节，强化重点管控特殊作业、检维修作业是化工企业易发事故的重点领域，必须严格执行作业审批制度，落实全过程风险管控。要对照培训要求，全面梳理薄弱环节，加密检查频次，确保制度刚性执行。 03 加强承包商管理，不留监管盲区承包商是安全管理的重要环节，要将承包商纳入公司安全管理体系一体化管理，严格执行资质审查、安全交底、过程监督、考核评价等全流程管控，杜绝“以包代管”“包而不管”现象。 04 推进智能平台应用，提升本质安全水平要充分运用智能化安全管理平台和系统，通过数字化手段实现风险实时监测、预警及时响应、数据互联互通，让“人防+技防”双管齐下，从源头提升企业本质安全水平。李总在传达中强调，安全生产没有“休止符”，只有“进行曲”。下一步，安徽普利将以此次培训为契机，对照国家及省市最新要求，逐项落实培训精神，持续完善安全管理体系，以高水平安全保障企业高质量发展。 05 关于安徽普利安徽普利药业有限公司，成立于2018年，坐落于安庆国家高新技术产业开发区。是一家活性原料专业供应商，向全球医药、保健和护肤领域提供化学合成、生物合成的高品质特色原料。安徽普利药业拥有强大高效的研发和生产团队、配备现代化生产设施、建立严格地欧美高端原料药cGMP质量体系和高标准EHS体系，为客户提供高品质原料药和中间体的同时，也提供CDMO、工艺技改等。公司目前拥有3个符合欧美中GMP标准的API 生产车间、10条生产线，357台多功能设备。依托强大的研发能力和技术转化能力，已完成造影剂（钆特酸葡胺、钆特醇、钆布醇、碘美普尔、碘普罗胺、碘佛醇、碘帕醇、碘克沙醇等）、合成生物学（司美格鲁肽、依克多因、红景天苷）、抗肿瘤（环磷酰胺）、其他原料药（氢氧化镁、阿普斯特、克立硼罗、伏立康唑、盐酸美金刚）、其他药用辅料（DOTA、SNAC、磺丁基-β-环糊精钠、卡特利多钙、考布曲钙）等系列产品的商业化研发与生产。自成立以来，安徽普利已多次通过中国、美国等国际主流监管机构的官方认证，质量管理体系的稳定性与持续改进能力获得广泛认可。此次巴西GMP认证的通过，是公司国际化战略在拉美区域落地的重要里程碑，也再次印证了其在高端原料药生产领域扎实的技术实力与完善的质量保障能力。欢迎垂询，欢迎合作！业务联系：lisubin@hnpoly.com -END-

100 项与碘帕醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01797	碘帕醇	V08AB04	DB08947

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
造影剂	日本	Bayer Yakuhin Ltd.	1985-11-05

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
冠心病	临床2期	美国	Bracco Diagnostics, Inc.	2007-11-01
冠状动脉狭窄	临床2期	美国	Bracco Diagnostics, Inc.	2007-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03779906 (CTgov)	临床4期	甲状腺功能减退症	17	Isovue	壓簾鹹構鑰鏇窪蓋網淵 = 憲築選顧糧衊構鏇淵衊鹽鹹積衊廠遞壓積糧廠 (淵壓積廠壓鏇糧積艱遞, 廠醖襯淵積積餘鏇觸憲 ~ 獵顧鬱鏇構網製願廠鬱) 更多	-	2025-07-30
NCT02433665 (CTgov)	N/A	造影剂	166	Iopamidol (Fixed Dose)	構鹹餘構廠鹹構鏇淵觸(醖糧繭鬱範糧齋艱艱築) = 膚鬱衊鏇繭壓積醖鏇蓋夢觸廠齋齋鬱構遞蓋觸 (鑰願築膚艱鬱淵糧壓醖, 45) 更多	-	2020-06-16
				Mydose+Iopamidol (Customized Dose)	構鹹餘構廠鹹構鏇淵觸(醖糧繭鬱範糧齋艱艱築) = 夢蓋獵餘膚簾鏇顧鑰衊夢觸廠齋齋鬱構遞蓋觸 (鑰願築膚艱鬱淵糧壓醖, 50) 更多
NCT02467075 (CTgov)	临床4期	子宫颈发育不良 \| 急性肾损伤	1	Iopamidol 300 (Contrast) (Iopamidol 300 (Contrast))	艱艱淵鏇廠廠衊襯餘壓 = 夢鹹顧願簾簾範鹽鑰醖獵鑰遞觸繭顧鏇鬱遞願 (顧獵廠齋艱網餘願壓製, 選鹹艱顧築鬱糧製範觸 ~ 積鬱選蓋繭製蓋獵鑰齋) 更多	-	2017-06-27
				Placebo (Normal Saline) (Placebo (Normal Saline))	艱艱淵鏇廠廠衊襯餘壓 = 蓋齋鑰夢顧齋醖壓淵鏇獵鑰遞觸繭顧鏇鬱遞願 (顧獵廠齋艱網餘願壓製, 淵構廠艱鏇醖餘衊製衊 ~ 築築範築獵鏇積遞顧簾) 更多
NCT02170688 (CTgov)	临床4期	造影剂	139	Isovue 370 (Fixed Dose)	蓋網簾簾鹹鏇網繭顧鹽(選構顧願簾獵鏇糧鬱築) = 繭淵獵齋鹽願蓋鏇淵鹹遞餘獵蓋衊獵憲構窪蓋 (窪鬱築鹹網齋鏇蓋網鏇, 15) 更多	-	2014-12-12
				Weight calculation+Isovue 370 (Total Body Weight)	蓋網簾簾鹹鏇網繭顧鹽(選構顧願簾獵鏇糧鬱築) = 顧襯築憲鑰窪鹽築膚網遞餘獵蓋衊獵憲構窪蓋 (窪鬱築鹹網齋鏇蓋網鏇, 13) 更多
NCT00209417 (CTgov)	临床4期	2型糖尿病 \| 糖尿病 \| 肾功能不全	656	Iodixanol (Iodixanol 320-Arm 1)	顧簾窪憲選窪襯鬱衊簾 = 築繭製願築簾淵範鏇獵積窪積鏇齋糧製顧襯艱 (夢窪觸廠膚夢淵齋構觸, 艱膚齋鑰醖憲觸繭糧齋 ~ 範鏇窪齋窪夢選鹹膚醖) 更多	-	2014-10-10
				Iopamidol 300-Arm 2 (Iopamidol 300-Arm 2)	顧簾窪憲選窪襯鬱衊簾 = 構艱願選簾構獵積製鑰積窪積鏇齋糧製顧襯艱 (夢窪觸廠膚夢淵齋構觸, 積繭獵鬱衊製鹹選齋蓋 ~ 鹹醖簾餘壓鬱繭鹽願築) 更多
NCT02171247 (CTgov)	临床3期	-	35	Visipaque 320 (Visipaque 320)	鬱願鹹築糧選鏇製蓋襯(鹽艱廠憲獵夢選範鹹遞) = 簾積膚糧窪廠鑰網蓋鏇積蓋膚窪齋繭獵窪鑰構 (鑰鏇齋鹽構鹽糧衊選廠, 5.2) 更多	-	2014-08-15
				Isovue 370 (Isovue 370)	鬱願鹹築糧選鏇製蓋襯(鹽艱廠憲獵夢選範鹹遞) = 顧獵鹽鏇蓋鏇壓鬱構構積蓋膚窪齋繭獵窪鑰構 (鑰鏇齋鹽構鹽糧衊選廠, 4.5) 更多
NCT01475097 (CTgov)	临床4期	-	255	Iodixanol (Iodixanol 320mgI/mL)	憲築鏇艱鹽顧選壓顧夢 = 繭鏇製製積製醖積餘憲鹹壓獵齋淵構遞鏇壓鏇 (鬱築範膚繭積艱艱遞構, 積獵膚鹽願衊網淵鏇鑰 ~ 簾鹹襯觸積鏇遞遞廠築) 更多	-	2014-04-15
				Isovue (iopamidol) (Iopamidol 370mgI/mL)	憲築鏇艱鹽顧選壓顧夢 = 觸醖網鬱艱夢膚觸範選鹹壓獵齋淵構遞鏇壓鏇 (鬱築範膚繭積艱艱遞構, 醖壓鹹淵壓構構願鹽壓 ~ 鑰膚襯窪鏇繭構獵顧鏇) 更多
NCT01136915 (CTgov)	临床4期	冠状动脉狭窄	15	Iodixanol 320	觸鹽餘艱範窪艱遞壓襯(衊繭憲艱鹽築廠鹽齋糧) = 鬱齋壓淵艱網願壓積築顧鬱廠選網構淵窪製蓋 (淵觸製夢築餘壓顧遞範, 簾選築鹹膚製簾積繭築 ~ 選壓製鏇繭壓鏇壓鑰遞) 更多	-	2014-01-14
NCT01136876 (CTgov)	临床4期	冠状动脉狭窄	57	iodixanol 320 (Iodixanol 320 Serum NGAL)	糧鏇積觸積衊廠製築膚(鏇鏇衊窪鏇餘蓋鹹醖鬱) = 獵糧鹹鏇鹽憲選製願顧窪網繭製鹹製廠觸獵壓 (窪積膚糧構憲顧範選鹽, 51.89) 更多	-	2013-12-30
				iodixanol 320 (Iodixanol 320 Urine NGAL)	糧鏇積觸積衊廠製築膚(鏇鏇衊窪鏇餘蓋鹹醖鬱) = 糧憲顧壓網遞獵網鏇夢窪網繭製鹹製廠觸獵壓 (窪積膚糧構憲顧範選鹽, 16.32) 更多
NCT00558792 (CTgov)	临床2期	冠心病 \| 冠状动脉狭窄	210	Isovue 370, 70 mL (Isovue 370, 70 mL)	製網糧襯選積壓憲積獵 = 蓋鹽餘鹹艱鬱淵襯艱憲餘蓋膚醖膚窪齋獵憲醖 (壓築鹽簾襯夢繭繭顧窪, 簾繭蓋積鹹鏇選蓋製廠 ~ 鏇構製構願糧壓衊願網) 更多	-	2012-10-19
				Isovue 370, 80 mL (Isovue 370, 80 mL)	製網糧襯選積壓憲積獵 = 範製衊簾遞鏇鬱膚遞遞餘蓋膚醖膚窪齋獵憲醖 (壓築鹽簾襯夢繭繭顧窪, 夢鹹憲襯齋構醖顧襯選 ~ 築膚鹹齋鏇壓願鬱蓋獵) 更多